Cargando…
A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes
Human African Trypanosomiasis is a vector-borne disease of sub-Saharan Africa that causes significant morbidity and mortality. Current therapies have many drawbacks, and there is an urgent need for new, better medicines. Ideally such new treatments should be fast-acting cidal agents that cure the di...
Autores principales: | De Rycker, Manu, O'Neill, Sandra, Joshi, Dhananjay, Campbell, Lorna, Gray, David W., Fairlamb, Alan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510075/ https://www.ncbi.nlm.nih.gov/pubmed/23209868 http://dx.doi.org/10.1371/journal.pntd.0001932 |
Ejemplares similares
-
Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase
por: Torrie, Leah S., et al.
Publicado: (2019) -
Development
of a 2,4-Diaminothiazole Series for the
Treatment of Human African Trypanosomiasis Highlights the Importance
of Static–Cidal Screening of Analogues
por: Cleghorn, Laura A. T., et al.
Publicado: (2023) -
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
por: De Rycker, Manu, et al.
Publicado: (2016) -
Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei
por: Wyllie, Susan, et al.
Publicado: (2016) -
Discovery of Indoline-2-carboxamide
Derivatives as
a New Class of Brain-Penetrant Inhibitors of Trypanosoma
brucei
por: Cleghorn, Laura A. T., et al.
Publicado: (2015)